Market Cap 19.27B
Revenue (ttm) 363.71M
Net Income (ttm) -913.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -251.24%
Debt to Equity Ratio 11.14
Volume 2,684,500
Avg Vol 3,219,026
Day's Range N/A - N/A
Shares Out 189.71M
Stochastic %K 95%
Beta 0.80
Analysts Strong Sell
Price Target $108.88

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 977 9900
Address:
700 US Highway 202/206, Bridgewater, United States
Night_Owl_Biotech
Night_Owl_Biotech Jun. 17 at 7:18 PM
BPMC today filed their 14D9 today that includes, among other data points, a review of revenue multiples paid in transactions considered peers to BPMC for valuation purposes. BPMC engaged Centerview & Jeffries who noted the following Year 4 multiples paid in recent M&A transactions. SWTX was acquired for 2.6X its FY2028 (or year 4) revenue projection which appears on the low end if these are appropriate peers for SWTX @patten1962 Other commercial-stage bios rumored to be M&A candidates, and hence may find these interesting, include; $MDGL $VRNA $INSM $LEGN $TARS This is not investment advice. We've never been able to ID M&A candidates.
1 · Reply
JoeB07
JoeB07 Jun. 17 at 12:22 PM
$INSM $GS 100 -> 112
1 · Reply
JoeB07
JoeB07 Jun. 17 at 2:26 AM
$INSM is now the $PLTR of bio/healthcare. The next $VRTX, but bigger. Like Humira and Keytruda combined. Brenso! Unbelievable potential. Going to ride the upper BBs through the analyst targets and beyond. Have fun. Get rich.!
0 · Reply
EatingCatPoop
EatingCatPoop Jun. 16 at 9:08 PM
$INSM who keeps buying this here when $LQDA just got approved for an arguably better drug for the same market and is valued at barely $1B??
1 · Reply
Holmes700R
Holmes700R Jun. 16 at 6:51 PM
$INSM crazy high valuation… needs a drop
1 · Reply
D_stocker
D_stocker Jun. 16 at 2:41 PM
$INSM I see they were able to sell shares at $91.68 instead of $96. I still don’t think that is a low enough number. Jim
1 · Reply
pianoman439
pianoman439 Jun. 13 at 11:43 PM
$INSM anyone gonna peg 💯 for the last trade AH?
0 · Reply
Bobray1
Bobray1 Jun. 13 at 7:32 PM
$INSM all u clowns predicting 60 to 80 dollars should move to another stock.
2 · Reply
Pegy
Pegy Jun. 13 at 4:52 PM
$INSM Yes, INSM can certainly dip below $95, and here’s why it’s a plausible scenario: ⸻ 🔹 1. Dilution & Offering Risk • The recent $750M offering at $96 adds ~4.5% more float, plus a greenshoe that could push dilution higher—this creates downward pressure . • Continued share selling by insiders and overhang could keep sentiment cautious . ⸻ 🔹 2. Technical Levels & Volatility • Daily support sits around $90.9, with next floors at $76.3 and $72.7 if initial levels fail . • Intraday expected range today spans $92.7–$101.0, meaning a dip under $95 is well within normal volatility . ⸻ 🔹 3. Mixed Technical Signals • TradingView shows a mix: short‑term oscillator is Sell, but moving averages lean Strong Buy—indicating a tug-of-war . • ChartMill sees neutral‑short trend with a strong support zone around $76.98 .
1 · Reply
caemeroon
caemeroon Jun. 13 at 4:09 PM
$INSM still confused on the price action vs volume because 7.8M shares are supposed to be hitting the market by EOD. Offering was announced yesterday after midnight. Volume yesterday was a little over 7M and today it is a little over 2M. I just don’t think these shares have hit yet or they aren’t being sold in very large blocks or something is amiss. Help me understand this one?
2 · Reply
Latest News on INSM
Is Insmed Stock Overvalued After The 45% Jump?

Jun 16, 2025, 5:05 AM EDT - 1 day ago

Is Insmed Stock Overvalued After The 45% Jump?


Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:55 PM EDT - 5 weeks ago

Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript


Insmed: Poised For Transformation Beyond ARIKAYCE

Apr 25, 2025, 11:58 AM EDT - 7 weeks ago

Insmed: Poised For Transformation Beyond ARIKAYCE


Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 12:50 PM EST - 4 months ago

Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript


Insmed To Present at March 2025 Investor Conferences

Feb 11, 2025, 8:00 AM EST - 4 months ago

Insmed To Present at March 2025 Investor Conferences


Insmed To Present at December 2024 Investor Conferences

Dec 2, 2024, 8:00 AM EST - 7 months ago

Insmed To Present at December 2024 Investor Conferences


Insmed To Present at November 2024 Investor Conferences

Nov 6, 2024, 8:00 AM EST - 7 months ago

Insmed To Present at November 2024 Investor Conferences


Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 2:31 PM EDT - 8 months ago

Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript


Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 4:11 PM EDT - 11 months ago

Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript


Insmed (INSM) CEO on the Company's Current Product Pipeline

Jun 4, 2024, 4:38 PM EDT - 1 year ago

Insmed (INSM) CEO on the Company's Current Product Pipeline


Night_Owl_Biotech
Night_Owl_Biotech Jun. 17 at 7:18 PM
BPMC today filed their 14D9 today that includes, among other data points, a review of revenue multiples paid in transactions considered peers to BPMC for valuation purposes. BPMC engaged Centerview & Jeffries who noted the following Year 4 multiples paid in recent M&A transactions. SWTX was acquired for 2.6X its FY2028 (or year 4) revenue projection which appears on the low end if these are appropriate peers for SWTX @patten1962 Other commercial-stage bios rumored to be M&A candidates, and hence may find these interesting, include; $MDGL $VRNA $INSM $LEGN $TARS This is not investment advice. We've never been able to ID M&A candidates.
1 · Reply
JoeB07
JoeB07 Jun. 17 at 12:22 PM
$INSM $GS 100 -> 112
1 · Reply
JoeB07
JoeB07 Jun. 17 at 2:26 AM
$INSM is now the $PLTR of bio/healthcare. The next $VRTX, but bigger. Like Humira and Keytruda combined. Brenso! Unbelievable potential. Going to ride the upper BBs through the analyst targets and beyond. Have fun. Get rich.!
0 · Reply
EatingCatPoop
EatingCatPoop Jun. 16 at 9:08 PM
$INSM who keeps buying this here when $LQDA just got approved for an arguably better drug for the same market and is valued at barely $1B??
1 · Reply
Holmes700R
Holmes700R Jun. 16 at 6:51 PM
$INSM crazy high valuation… needs a drop
1 · Reply
D_stocker
D_stocker Jun. 16 at 2:41 PM
$INSM I see they were able to sell shares at $91.68 instead of $96. I still don’t think that is a low enough number. Jim
1 · Reply
pianoman439
pianoman439 Jun. 13 at 11:43 PM
$INSM anyone gonna peg 💯 for the last trade AH?
0 · Reply
Bobray1
Bobray1 Jun. 13 at 7:32 PM
$INSM all u clowns predicting 60 to 80 dollars should move to another stock.
2 · Reply
Pegy
Pegy Jun. 13 at 4:52 PM
$INSM Yes, INSM can certainly dip below $95, and here’s why it’s a plausible scenario: ⸻ 🔹 1. Dilution & Offering Risk • The recent $750M offering at $96 adds ~4.5% more float, plus a greenshoe that could push dilution higher—this creates downward pressure . • Continued share selling by insiders and overhang could keep sentiment cautious . ⸻ 🔹 2. Technical Levels & Volatility • Daily support sits around $90.9, with next floors at $76.3 and $72.7 if initial levels fail . • Intraday expected range today spans $92.7–$101.0, meaning a dip under $95 is well within normal volatility . ⸻ 🔹 3. Mixed Technical Signals • TradingView shows a mix: short‑term oscillator is Sell, but moving averages lean Strong Buy—indicating a tug-of-war . • ChartMill sees neutral‑short trend with a strong support zone around $76.98 .
1 · Reply
caemeroon
caemeroon Jun. 13 at 4:09 PM
$INSM still confused on the price action vs volume because 7.8M shares are supposed to be hitting the market by EOD. Offering was announced yesterday after midnight. Volume yesterday was a little over 7M and today it is a little over 2M. I just don’t think these shares have hit yet or they aren’t being sold in very large blocks or something is amiss. Help me understand this one?
2 · Reply
pianoman439
pianoman439 Jun. 13 at 1:38 PM
$INSM following an identical pattern to Brensocatib data release a year ago.
1 · Reply
caemeroon
caemeroon Jun. 13 at 1:34 PM
$INSM at least this morning, so far, I stand corrected.
1 · Reply
Survivingcovid
Survivingcovid Jun. 13 at 11:59 AM
$INSM perfect time for the company to unload those shares today. PT $75 by next week.
0 · Reply
JoeB07
JoeB07 Jun. 13 at 11:20 AM
$INSM going to surge at the open. Have fun.
1 · Reply
Holmes700R
Holmes700R Jun. 13 at 9:52 AM
$INSM wouldn’t be suprised to see this get shorted down to $60 again over time… people buying these additional shares will be shorting them immediately for sure.
0 · Reply
caemeroon
caemeroon Jun. 13 at 1:40 AM
$INSM bid is at 91 after hours (it’s after hours though right?) well the ask is $95. Tomorrow the bottom falls out I think. 7.8M share offering “to be completed by Friday” per the press release. I could be wrong but I don’t know how it holds $90-$92 region
0 · Reply
Survivingcovid
Survivingcovid Jun. 12 at 11:36 PM
$INSM Adding 7.5 million shares of stock (known as a share offering, stock dilution, or equity offering) can have several risks for a company like INSM and its existing shareholders: * **Dilution of Ownership:** This is the most significant risk. Existing shareholders' percentage ownership of the company is reduced because the pie (number of shares) has gotten bigger. Their existing shares now represent a smaller fraction of the company's total equity. Dilution of Earnings Per Share (EPS):If the company's earnings don't increase proportionally with the increased number of shares, the EPS will decrease. This means each share represents a smaller claim on the company's profits. This can lead to a decrease in the stock price. Downward Pressure on Stock Price:The market often reacts negatively to news of a share offering, even if the company is doing well. This is because: Increased Supply:More shares available can temporarily increase selling pressure, driving the price down.
0 · Reply
Holmes700R
Holmes700R Jun. 12 at 9:35 PM
$INSM the shares bought will be hedged short for certain to make money going down…. Anyone that things otherwise is stupid…. Why else would you do it? We can all buy shares at $96 don’t need extra shares to do it
0 · Reply
BullRun4
BullRun4 Jun. 12 at 7:24 PM
$INSM public offer of 7.5 million shares, diluting value. More offers to come soon. They need plenty more of capital is what I hear.
0 · Reply
caemeroon
caemeroon Jun. 12 at 5:47 PM
$INSM they are selling approx 7.5M shares, this thing has held up but the press release says the sale will be done by tomorrow at $96 per share. It’ll come down, it won’t stay up here this time. IMO.
2 · Reply
look2theblue
look2theblue Jun. 12 at 3:14 PM
$ITRM Published in February. Mycobacterium is a BIG issue. Go look at $INSM Arikayce. Sulopenem could be used for systemic MAC. https://pubmed.ncbi.nlm.nih.gov/39714147/
0 · Reply
Holmes700R
Holmes700R Jun. 12 at 2:05 PM
$INSM market cap of 17B vs LQDA which is selling a product we have at phase 2b in only 1B I’m going to switch sides today I think.
0 · Reply